Mall of America

NANOBIOTIX Provides Third Quarter Operational and Financial Update

Wednesday, October 20, 2021 - 9:15pm

Nanobiotix reported cash, cash equivalents, and short-term investments totaling 89.8 million as of September 30, 2021, compared to 119.2M as of December 31, 20201.

Key Points: 
  • Nanobiotix reported cash, cash equivalents, and short-term investments totaling 89.8 million as of September 30, 2021, compared to 119.2M as of December 31, 20201.
  • Given the physical MoA, Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors.
  • Such forward-looking statements are made in light of information currently available to us and based on assumptions that Nanobiotix considers to be reasonable.
  • 1 It being specified that the company did not generate any revenue during the third quarter of 2021, this following the termination of the PharmaEngine partnership.

CytoReason Collaborates with Merck KGaA, Darmstadt, Germany, on Cancer Immunotherapy Drug

Wednesday, October 20, 2021 - 2:28pm

CytoReason will use its machine learning platform and proprietary computational disease models to verify Merck KGaA, Darmstadt, Germany's therapeutic hypothesis, providing a deeper analysis of the drug's MoA.

Key Points: 
  • CytoReason will use its machine learning platform and proprietary computational disease models to verify Merck KGaA, Darmstadt, Germany's therapeutic hypothesis, providing a deeper analysis of the drug's MoA.
  • "We are thrilled to be working with the talented team at Merck KGaA, Darmstadt, Germany," said David Harel, CEO and Co-founder of CytoReason.
  • This collaboration might help identify which type of tumor the drug will be most effective for, and has the potential to save the lives of millions who suffer from cancer."
  • CytoReason is a technology startup that has developed a computational model of the human body.

Wisdom Gaming and Mall of America Announce First-of-its-Kind Partnership to Create Midwest Esports Hub

Thursday, October 14, 2021 - 2:00pm

The partnership was born out of a shared goal of making the Twin Cities a true hub for the multi-billion-dollar esports and gaming industry.

Key Points: 
  • The partnership was born out of a shared goal of making the Twin Cities a true hub for the multi-billion-dollar esports and gaming industry.
  • "We are thrilled to partner with Wisdom Gaming, leveraging their expertise in the space to establish Mall of America as the premiere esports destination hub for guests, and global esports fans alike."
  • Wisdom Gaming is a leader in esports production, building global communities across the gaming ecosystem.
  • Wisdom Gaming offers turnkey creative and production services, tournament organization, and marketing strategy for brands and publishers passionate about establishing their legacy in esports and gaming.

Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature Medicine

Monday, October 11, 2021 - 1:00pm

TEL AVIV, Israel, October 11, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the one-year results of the global Phase 2b randomized placebo-controlled ARREST Trial of Aramchol in patients with NASH have been published in Nature Medicine ( https://www.nature.com/articles/s41591-021-01495-3 ).

Key Points: 
  • TEL AVIV, Israel, October 11, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the one-year results of the global Phase 2b randomized placebo-controlled ARREST Trial of Aramchol in patients with NASH have been published in Nature Medicine ( https://www.nature.com/articles/s41591-021-01495-3 ).
  • The ARREST Phase 2b study randomized 247 patients with NASH confirmed by liver biopsy.
  • Data from the ARREST Phase 2b study published in this paper demonstrate how the mechanism of action of Aramchol translates into clinical performance.
  • Our lead compound, Aramchol, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study.

2021 Report on Proliferative Vitreoretinopathy (Ophthalmology) Drugs In Development - ResearchAndMarkets.com

Thursday, October 7, 2021 - 1:47pm

The "Proliferative Vitreoretinopathy (PVR) (Ophthalmology) - Drugs In Development, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Proliferative Vitreoretinopathy (PVR) (Ophthalmology) - Drugs In Development, 2021" report has been added to ResearchAndMarkets.com's offering.
  • This report provides an overview of the Proliferative Vitreoretinopathy (Ophthalmology) pipeline landscape.
  • The publisher's Pharmaceutical and Healthcare latest pipeline guide Proliferative Vitreoretinopathy - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Proliferative Vitreoretinopathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Proliferative Vitreoretinopathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Proliferative Vitreoretinopathy (PVR) and features dormant and discontinued projects.

2021 Report on Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorder) Drugs In Development - ResearchAndMarkets.com

Thursday, October 7, 2021 - 12:56pm

The "Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorder) - Drugs In Development, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorder) - Drugs In Development, 2021" report has been added to ResearchAndMarkets.com's offering.
  • Proliferative diabetic retinopathy (PDR) is the most severe type of diabetic retinopathy.
  • The publisher's Pharmaceutical and Healthcare latest pipeline guide Proliferative Diabetic Retinopathy - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Proliferative Diabetic Retinopathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Proliferative Diabetic Retinopathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Proliferative Diabetic Retinopathy (PDR) and features dormant and discontinued projects.

NANOBIOTIX to Present First Survival Data From Priority Head and Neck Cancer Program Among Five Presentations at the 2021 Annual Meeting of the American Society for Radiation Oncology

Wednesday, October 6, 2021 - 9:15pm

Bringing disruptive therapeutic solutions that expand treatment possibilities for patients with cancer starts with making a meaningful impact on survival, said Laurent Levy, co-founder and chairman of the executive board of Nanobiotix.

Key Points: 
  • Bringing disruptive therapeutic solutions that expand treatment possibilities for patients with cancer starts with making a meaningful impact on survival, said Laurent Levy, co-founder and chairman of the executive board of Nanobiotix.
  • NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) as the primary development pathway.
  • For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter .
  • Such forward-looking statements are made in light of information currently available to us and based on assumptions that Nanobiotix considers to be reasonable.

eSight Announces New Partnership with Merlin Entertainments to Change Lives Around The World

Tuesday, October 5, 2021 - 2:00pm

TORONTO, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Leading vision-enhancement platform, eSight , announces a new partnership with Merlin Entertainments , one of the largest attractions operators in the world.

Key Points: 
  • TORONTO, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Leading vision-enhancement platform, eSight , announces a new partnership with Merlin Entertainments , one of the largest attractions operators in the world.
  • In addition, eSight and Merlin will work together to create more inclusive initiatives for future guests with low vision or legal blindness.
  • eSight and Merlin Entertainments are working together to create once-in-a-lifetime experiences at Merlin Entertainments' LEGOLAND Parks, LEGOLAND Discovery Center and SEA LIFE locations.
  • With Merlin Entertainments expertise, we are able to give people with visual impairments a day theyll never forget, said Robert Vaters, CEO of eSight.

CytoReason and Summit Pharmaceuticals International Announce the Introduction of an AI Platform to One of Japan's Top Pharmaceutical Companies

Thursday, September 30, 2021 - 6:00am

TOKYO and TEL AVIV, Israel, Sept. 30, 2021 /PRNewswire/ -- CytoReason, an AI company developing computational disease models for discovery and clinical drug development, and Summit Pharmaceuticals International (SPI), a Japanese company providing service and products to the pharmaceutical industry (wholly-owned subsidiary of Sumitomo Corporation), today announced that CytoReason has entered the Japanese market, with its technology being utilized by one of Japan's top pharmaceutical companies.

Key Points: 
  • This is the first-ever announced collaboration between an Israeli company and a Japanese pharmaceutical company to bring AI to clinical drug development.
  • The collaboration will explore the relationship between disease mechanisms and drug MoA in order to increase the drug's valuation in immunology.
  • CytoReason helps pharma and biotech companies accelerate drug discovery and development with the use of its cell-centered computational models and proprietary data.
  • R&D using AI technology is becoming essential in the pharmaceutical field and the industry has taken keen interest in CytoReason's technology.

NANOBIOTIX Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May “Reprogram” the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect

Tuesday, September 28, 2021 - 9:15pm

We are proud to collaborate with MD Anderson as we seek to validate the broadly applicable, local and systemic potential benefits of NBTXR3.

Key Points: 
  • We are proud to collaborate with MD Anderson as we seek to validate the broadly applicable, local and systemic potential benefits of NBTXR3.
  • Immune checkpoint inhibitors (ICIs) such as anti-PD-1 have shown tremendous promise for the treatment of some patients with metastatic tumors.
  • To date, however, most patients with cancer have shown resistance to anti-PD-1, limiting the effect of this combination.
  • NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) as the primary development pathway.